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Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are
aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic
virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication
competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway.
This virus has proven to be safe and effective in adult gliomas. Here we report that the
administration of Delta-24-RGD is safe in mice and results in a signiﬁcant increase in survival
in immunodeﬁcient and immunocompetent models of pHGG and DIPGs. Our results show
that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune
response elicited against the tumor. Altogether, our data highlight the potential of this
virus as treatment for patients with these tumors. Of clinical signiﬁcance, these data have
led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG
(NCT03178032).
https://doi.org/10.1038/s41467-019-10043-0 OPEN
1 Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain. 2 Program of Solid Tumors, Center for the Applied Medical Research (CIMA),
University of Navarra, Navarra, Pamplona, Spain. 3 Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain. 4Department of Neurology,
Clínica Universidad de Navarra, Pamplona, Spain. 5Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain. 6Department of
Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain. 7Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton,
London, Surrey SM2 5NG, UK. 8Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey SM2 5NG, UK.
9Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
10Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 11 Division of Pediatric Oncology, The Johns Hopkins
University School of Medicine, Baltimore, MD, USA. 12Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA. 13Department of
Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital,
Chicago, IL, USA. 14CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France. 15Division of Pediatric Neurosurgery,
Department of Surgery, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA. 16Department of NeuroOncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA. 17Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Correspondence and requests for materials should be addressed to C.G.-M. (email: cmanzano@mdanderson.org) or to M.M.A. (email: mmalonso@unav.es)
NATURE COMMUNICATIONS |         (2019) 10:2235 | https://doi.org/10.1038/s41467-019-10043-0 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Pediatric high-grade glioma (pHGG), including diffuseintrinsic pontine glioma (DIPG), are aggressive solidtumors that develop during childhood. pHGG was tradi-
tionally considered similar to adult high-grade gliomas; however,
over the last decade, an emerging plethora of genomic data has
changed our understanding of both pHGG and DIPG and
demonstrated that these cancers are indeed very different entities
from their adult counterparts1–3. The knowledge acquired from
genomic data has supported the 2016 WHO reclassiﬁcation of
central nervous system (CNS) tumors in which DIPG is included
in a new category named diffuse midline glioma (DMG) H3-
K27M-mutant4.
Regarding their epidemiology, these two malignancies account
for ~ 8–12% of all CNS tumors that arise in children. Because the
incidence of this disease is ~ 85 per 100,000, similar to most
pediatric tumors, pHGG and DIPG are considered orphan dis-
eases5. The incidence peak of pHGG and DIPG appears in
patients aged between 6 and 9 years6. The standard treatment for
pHGG is maximal surgical resection, followed by radiotherapy
and/or temozolomide cycles7. Unfortunately, surgery is not a
therapeutic option for DIPG, and the standard of care is radio-
therapy (RT). RT improves the quality of life and survival of these
children; however, RT is not curative8. Despite the signiﬁcant
number of clinical trials investigating pHGG and DIPG, patient
outcomes have continued to be dismal over the last four
decades9,10. The implementation of alternative therapies that
challenge the actual therapeutic paradigm could provide a
breakthrough in the treatment of these tumors.
Virotherapy is emerging as an alternative treatment for cancer.
In fact, the recent approval of T-VEC (Talimogene laherpar-
epvec), which is an oncolytic herpes virus, by the FDA for
metastatic melanoma has enabled the possibility to use other
oncolytic viruses as standard treatment for cancer11.
Delta-24-RGD is a replicative oncolytic adenovirus speciﬁ-
cally modiﬁed to destroy cancer cells12,13. A genetic modiﬁca-
tion in the E1A viral gene, which is a 24-base pair deletion
responsible for pRB protein binding, confers this adenovirus
with selectivity to cancer cells. The addition of an RGD sequence
in the viral ﬁber improves its infectivity, allowing the virus
to interact with ανβ3 and ανβ5 integrins that are overexpressed
in a wide range of tumors, including glioma cells. In fact, several
clinical trials involving adult glioma patients have shown that
the intratumoral administration of Delta-24-RGD (DNX-2401
in the clinic) is safe and provides a therapeutic advantage in
many patients14. Recent studies have demonstrated that the
antitumor effect displayed by oncolytic adenoviruses is not only
related to their intrinsic oncolytic effect but also to the triggering
of an immune response. Tumor infection elicits speciﬁc anti-
tumor immunity in adult mouse glioma models. Importantly,
these results have been conﬁrmed in patients, and histological
analyses of tumor resections after Delta-24-RGD administration
have shown an increased number of inﬁltrated immune popu-
lations in the tumors, suggesting that an immune-mediated
antiglioma response occurred14. These results encourage the
translation of Delta-24-RGD as a feasible treatment for pediatric
brain tumors.
In this study, we evaluate the antiglioma effect of Delta-24-
RGD in pHGG and DIPG models. Our data show that Delta-24-
RGD results in a signiﬁcant antitumor effect in vitro in a panel
of cell lines and in vivo in pHGG and DIPG orthotopic immu-
nosuppressed and immunocompetent models. Our results show
that in addition to the oncolytic effect, Delta-24-RGD adminis-
tration triggers an antitumor immune response. These promising
preclinical results paved the way for a phase I/II clinical trial
investigating DNX-2401 (NCT03178032) for the treatment of
newly diagnosed DIPGs at our institution15.
Results
Delta-24-RGD determinants of infection and replication in
pHGG/DIPG. To evaluate whether pHGG and DMG/DIPG are
susceptible to viral infection, using a cohort of 220 patient sam-
ples of pHGG and DMG/DIPG previously published1, we per-
formed “in silico analyses” of the expression of the following
main receptors that use Delta-24-RGD to enter cells: Coxsackie
adenovirus receptor (CAR; CXADR), integrinαVβ3 (ITGA3),
integrinαVβ5 (ITGA5), and integrinαVβ (ITGAV). Our analyses
revealed that independently of the molecular group to which the
patients were assigned, all patients expressed signiﬁcant amounts
of these genes (Fig. 1a and Supplementary Fig. 1a). These data
indicate that these tumors are potentially susceptible to Delta-24-
RGD infection. Then, as Delta-24-RGD replication is dependent
on an aberrant RB pathway, we analyzed the expression and
ampliﬁcations/deletions of the genes involved in the RB pathway,
speciﬁcally cdk4/6, cyclin D1, RB, and E2F1. We found that
different RB pathway proﬁles are related to the different mole-
cular subgroups (H3.3G34R, H3.3K27M, H3.1K27M, IDH1,
BRAF_PXA, and HGG_GBM_wt) (Fig. 1b, Supplementary
Fig. S1b). cdk4/6 had a modest rate in all subgroups; meanwhile,
CCND1 ampliﬁcation was only observed in the H3.3K27M
molecular subgroup. RB deletions were only present in the IDH1
group. However, CDKN2A deletions were found in almost all
subgroups (Fig. 1b), and this gene encodes p16INK4a and p14arf.
As a result of all these deletions, we observed increased E2F1
expression, which, in turn, activates the viral transcriptional
program and ﬁnally its replication (Supplementary Fig. 1c). In
summary, these results highlight the suitability of Delta-24-RGD
as a possible therapy for pHGG and DMG, including DIPGs.
Delta-24-RGD antiglioma effect in human pHGG and DIPG
cell lines. The analysis of viral receptor (ανβ3, ανβ5 integrin, and
CAR) expression in the membrane of a panel of pHGGs and
DIPGs revealed that all display these receptors in their mem-
brane, suggesting that they could be infected by an adenovirus.
Interestingly, the CAR receptor was abundantly expressed in all
cell lines assessed (ranging from 40 to 90%) (Fig. 2a). These
results are consistent with the expression data observed in the
patients (Fig. 1). Then, we tested the capacity of Delta-24-RGD to
infect pHGG (CHLA-03-AA, CHLA-200, PBT-24, SJ-GBM2, and
SF188) and DIPG (TP54, TP80, TP83, TP84, and SU-DIPG IV)
cell lines. We infected these cell lines with a replication-deﬁcient
Ad5-GFP-RGD adenovirus at 10 and 100 MOIs and quantiﬁed
the % of GFP-expressing cells by ﬂow cytometry. We observed
that at the 10 MOI, > 50% of the cells were infected, and 100%
infection of the cell lines was achieved at 100 MOI (Fig. 2b,
Supplementary Fig. 2a). In general, the pHGG cell lines were
more easily infected than the DIPG cell lines.
Following the infection of the indicated cell lines with
increasing amounts of Delta-24-RGD, E1A, and ﬁber, which are
an early protein and master regulator of the viral cycle and a late
protein, respectively, showed a robust expression. The expression
of these proteins was patent even at the smallest dose of ﬁve
MOI (Fig. 2c and Supplementary Fig. 2b). These results suggest
that Delta-24-RGD is able to undergo a viable viral cycle in
pHGG and DIPG cells. Furthermore, Delta-24-RGD efﬁciently
replicated with at least an increment of two logarithms in viral
progeny compared with the input virus (106 pfu, dashed line)
in all cell lines tested after 72 h of infection (Fig. 2d). Overall,
the virus showed a better replication in the pHGG cell lines
when compared with the DIPG cell lines (P= 0.03; Supplemen-
tary Fig. 2c).
Subsequently, we evaluated the antitumor effect of Delta-24-
RGD in the pHGG (N= 5) and DIPG (N= 7) cell lines.
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The Delta-24-RGD treatment resulted in a signiﬁcant antitumor
effect in all cell lines tested. The IC50 ranged between 3.6 and 68
MOIs in the DIPG cell lines and 0.8 and 32 MOIs in the pHGG
cell lines (Fig. 2e, Supplementary Fig. 3 and Table 1). PBT-24,
which is a pHGG cell line in which Delta-24-RGD presented the
best infectivity and replication capacity, also displayed the lowest
IC50. In summary, these results demonstrate that Delta-24-RGD
is able to infect, replicate and exert a signiﬁcant cytotoxic effect
in all pHGG and DIPG cell lines tested.
Delta-24-RGD extends survival in pHGG and DIPGs ortho-
topic models. Given the encouraging in vitro results, we eval-
uated the antitumor effect of Delta-24-RGD in vivo in two
orthotopic models of DIPG (TP80 and TP54) and two models
of pHGG (CHLA-03-AA and PBT-24). A single dose (108 pfu per
animal) of Delta-24-RGD was intratumorally injected on day 3
after cell implantation. The mice were monitored during the
experiment until physical decline, such as weight loss or ataxia,
was observed. The survival analyses showed that Delta-24-RGD
was able to signiﬁcantly increase (P= 0.024, Log-rank test) the
overall survival of mice bearing TP80 with a median survival of
217 days. The Delta-24-RGD administration increased survival
by an average of 40 days (P= 0.024, Log-rank test), and the
treatment resulted in 44% of long-term survivors in the treated
group (Fig. 3a and Supplementary Fig. 4a). Mice bearing the
TP54 cell line in the pons exhibited a median survival of
83.5 days, whereas the mice treated with Delta-24-RGD exhibited
a median survival of 95.5 days (P= 0.04, Log-rank test) (Fig. 3b
and Supplementary Fig. 4a). The median survival of the mice
bearing CHLA-03-AA was 46 days, whereas the Delta-24-RGD-
treated mice had an increased overall survival by 53 days,
resulting in 36% of long-term survivors free of disease (P <
0.0001, Log-rank test) (Fig. 3c and Supplementary Fig. 4a).
Finally, compared with the mice bearing the PBT-24 control
(survival of 75 days), the treated mice displayed a median
survival of 100.5 days (Log-rank test; P= 0.0013), and there were
33% of long-term survivors in the treatment group (Fig. 3d and
Supplementary Fig. 4a).
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Fig. 1 Delta-24-RGD determinants of replication and infection in pHGG and DIPG. a Assessment of integrin and CAR expression in pHGG and DIPGs.
b Characterization of ampliﬁcations and deletions of RB pathway genes in pHGG and DIPGs. Source data are provided as a Source Data ﬁle
Table 1 Median-effect doses (IC50) of Delta-24-RGD in
pHGG and DIPG cell lines
Cell lines IC50 (MOIs ± SD)
pHGG CHLA-03-AA 10.22 ± 3.1
PBT-24 0.8 ± 0.06
SF188 9.6 ± 0.5
SJ-GBM2 32 ± 7.1
CHLA-200 5 ± 0.06
DIPG TP54 9.6 ± 3.1
DIPG IV 3.6 ± 1.8
TP80 39.7 ± 10.9
TP83 51.9 ± 13.7
TP84 68 ± 4.1
JHH-DIPG1 26.2 ± 1.5
JHH-DIPG16A 9.6 ± 5.9
The IC50 value (MOIs) is the median-effect dose (dose affecting 50% of the cells, i.e., 50%
survival). IC50= 50% inhibitory concentration; MOI=multiplicity of infection
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The pathological analyses of the tumors showed the highly
inﬁltrative nature of the TP80 cell lines recapitulating the invasive
phenotype displayed by midline gliomas. The hematoxylin/eosin
staining revealed that the tumor cells inﬁltrated the whole-brain
parenchyma, including other structures, such as the cerebellum
(Fig. 3e). TP54, CHLA-03-AA, and PBT-24 are very proliferative
tumors with deﬁned borders. The treatment with Delta-24-RGD
resulted in smaller tumors and long-term survivors free of disease
(Fig. 3f). E1A and hexon expression was detected in the brains of
mice treated with the virus (Fig. 3g and Supplementary Fig. 4b, c).
The long-term free of disease survivors did not display the
expression of viral proteins.
Next, we assessed the antitumor effect of the viral treatment in
already established tumor tumors generated by the CHLA-03-AA
and PTB-24 (15 days after cell injection; Supplementary Fig. 4d).
The median survival of the mice bearing CHLA-03-AA was
40 days, whereas the Delta-24-RGD-treated mice had an
increased median survival of 14.5 days, resulting in 33% of
long-term survivors free of disease (Log-rank test; P= 0.005)
(Fig. 3h). Mice bearing PBT-24 cell line and treated with Delta-
24-RGD also displayed a signiﬁcant increase in overall survival
(82 days), compared with the mice bearing the PBT-24 control
(76 days; P= 0.04, Log-rank test) (Fig. 3i).
Delta-24-RGD antitumor effects in murine DIPG cell lines.
Clinical trials investigating oncolytic viruses have uncovered that
the efﬁcacy of these viruses is partially owed to their potential to
awaken the immune system14,16. Therefore, our following step
was to assess the immune response to Delta-24-RGD treatment in
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Fig. 2 Delta-24-RGD exerts a potent oncolytic effect in DIPG and pHGG cell lines. a Flow cytometry analyses of CAR and integrin expression. DIPG and
pHGG cell lines were incubated with ﬂuorescent antibodies against ανβ3 and ανβ5 integrins and CAR. The data are shown as the relative percentage (mean ±
SD) of positive expression scored among 10,000 cells. b Assessment of infectivity in DIPG and pHGG cell lines. The indicated cell lines were infected with a
replication-deﬁcient construct expressing a modiﬁed ﬁber knob (AdGFP-RGD). The data are shown as the relative percentage (mean ± SD) of GFP-positive
cells scored among 10,000 cells per treatment group. c Assessment of viral protein expression in pHGG and DIPG cell lines infected with Delta-24-RGD by
western blotting. One representative blot is shown of three independent experiments. d Quantiﬁcation of Delta-24-RGD replication in the indicated cell lines.
Viral titers were determined three days after infection at an MOI of 10 (106 pfu/ml) by an anti-hexon staining-based method in 293 cells and expressed as
plaque-forming units (pfu) per milliliter. The dashed line indicates the input virus. The data are shown as the mean ± SD of three independent experiments.
e Cell proliferation analyses of Delta-24-RGD-infected DIPG and pHGG cell lines. Cell viability was assessed using MTS assays 5 days after infection.
The data are shown as the percentage (mean ± SD of three independent experiments) of cells alive after infection with Delta-24-RGD at the indicated
multiplicities of infection (MOIs) relative to the non-infected cells (control, equal to 100%). Source data are provided as a Source Data ﬁle
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10043-0
4 NATURE COMMUNICATIONS |         (2019) 10:2235 | https://doi.org/10.1038/s41467-019-10043-0 | www.nature.com/naturecommunications
an immunocompetent model. Thus, we used XFM and NP53
murine cell lines derived from tumors arising in the pons of
genetically modiﬁed mice17,18. The in vitro analyses showed that
these cell lines were highly susceptible to adenoviral infection,
and at 10 MOI, ~ 100% of the cells were infected (Fig. 4a). One
caveat to studies of the immune response to adenoviral infection
and replication in immunocompetent mice models is that ade-
noviral replication (serotype 5) is hindered in murine cell lines19.
First, we assessed the expression of ﬁber protein in previously
infected NP53 and XFM cell lines. Interestingly, we observed the
expression of this late viral protein, suggesting that viral repli-
cation might occur in these cells (Fig. 4b). Surprisingly, NP53 and
XFM were semi-permissive to viral replication as shown by the
viral titers in these cells, which were albeit lower than those in
their human counterparts. We observed that the virus replication
was higher in NP53 or XFM infected with 300 MOIs (two-tailed
Student t test; P= 0.07 and P= 0.005, respectively) when com-
pared with the initial inoculum (Fig. 4c). We also observed the
assembly of virions in the cell nucleus (Fig. 4d). Finally, the
cytotoxicity analyses revealed that Delta-24-RGD was able to kill
NP53 and XFM with IC50s of 104 and 36 MOIs, respectively
(Fig. 4e).
Delta-24-RGD administration in murine DIPG-
immunocompetent models. We have clinical evidence of the
safety of Delta-24-RGD in supratentorial tumors14. However,
Delta-24-RGD administration into the pons could lead to
inﬂammation and, if uncontrolled, fatalities speciﬁcally in DIPG
patients. Therefore, we performed a dose escalation study to
conﬁrm the lack of toxicity in this model. Previously, we had
performed kinetics studies to evaluate the most suitable number
of cells for these experiments (Supplementary Fig. 5a). Mice
bearing DIPG cells in the pons were intratumorally treated with
virus at doses ranging from 106 to 108 pfu in increments of a half
logarithm and followed for 15 days to assess toxicity. No dose
analyzed caused a lethal reaction (Supplementary Table 2). In
addition, we evaluated one injection versus three viral injections
every other day at the maximum dose (108 pfu). Again, under
this schedule, we did not observe any toxicity (Supplementary
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Fig. 3 Delta-24-RGD increases overall survival in DIPG and pHGG models. Tumors were developed by orthotopic intracranial injection of 500,000 cells in
female nude mice. a Kaplan–Meier survival curves of Delta-24-RGD (108 pfu)- and control (PBS)- treated athymic mice bearing a TP80 (Control N= 8,
Delta-24-RGD-treated N= 9), b TP54 (Control N= 8, Delta-24-RGD-treated N= 9), c CHLA-03-AA (Control N= 9, Delta-24-RGD-treated N= 11), and d
PBT-24 (Control N= 9, Delta-24-RGD-treated N= 10). Animals were treated 3 days post-tumor cell injection. The shaded area represents a 50-day
interval from the time of cell implantation. Log-rank test was used as statistical analyses. e Representative images of the histopathological analyses of TP80
and TP54 (H&E) of longitudinal slides of control (left images) and Delta-24-RGD-treated tumors (right image). f Representative images of the
histopathological analyses of CHLA-03-AA and PBT-24 (H&E) (magniﬁcation × 1) of control (left image) and Delta-24-RGD-treated (right images). Mice
were treated with either PBS (control) or Delta-24-RGD 3 days post injection. For comparison studies, analyzed brains are derived from mice that died at a
similar time point in both groups: CHLA-03-AA= 50 ± 10 days; PBT-24= 60 ± 5 days; TP80= 200 ± 5 days; TP54= 90 ± 5 days. g Representative images
of H&E, hexon, and E1A immunostaining of TP80 or CHLA-03-AA tumors, non-treated, or treated with Delta-24-RGD (scale bars, 100 μm). Images
correspond to the brains shown in e, f. h, i Kaplan–Meier survival curves of established tumors h CHLA-03-AA (Control N= 10, Delta-24-RGD-treated N
= 10) and i PBT-24 (Control N= 8, Delta-24-RGD-treated N= 9) treated with Delta-24-RGD 15 days post cell implantation. The shaded area represents a
50-day interval from the time of cell implantation. Source data are provided as a Source Data ﬁle
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Table 3). As weight loss is a sign of toxicity, we monitored this
parameter for 15 days after the virus injection. The animals did
not display a signiﬁcant weight variation related with PBS or
Delta-24-RGD administration (Supplementary Fig. 5b). The his-
tology analyses of the DIPG tumors in vivo in mice bearing either
NP53 or XFM cells showed that after administration of Delta-24-
RGD E1A could be detected in the tumor in both models (Sup-
plementary Fig. 5c). In addition, administration of Delta-24-RGD
signiﬁcantly increased (two-tailed Student t test; P < 0.0001) the
number of CD3-positive cells inﬁltrating the tumor mass com-
pared with that in their counterpart controls (Fig. 5a, b and
Supplementary Fig. 6a). Moreover, higher CD3+ levels corre-
sponded to higher numbers of CD4- and CD8-positive cells (two-
tailed Student t test; P= 0.0002, P= 0.0005, respectively) and a
decrease in FoxP3+/CD4+, which was not signiﬁcant in the
NP53-bearing mice (two-tailed Student t test, P= 0.07) but was
signiﬁcant in the XFM-bearing animals (two-tailed Student t test
P= 0.03) (Fig. 5c–e, and Supplementary Fig. 6b, c). The mRNA
expression analysis in the tumors treated with Delta-24RGD
revealed higher IFN gamma, CD8a, and CD4 mRNA levels
compared with those in the PBS-treated tumors (Fig. 5f and
Supplementary Fig. 6d). Moreover, splenocytes extracted from
mice treated with the adenovirus were co-cultured with tumor
cells. The splenocytes from the Delta-24-RGD-treated NP53 and
XFM-bearing mice expressed signiﬁcantly more IFN gamma than
those extracted from the PBS-treated mice (two-tailed Student
t-test; P= 0.001, P= 0.0005, respectively) (Fig. 5g and Supple-
mentary Fig. 6e), suggesting that there is a speciﬁc antitumor
immune response.
Once we had proof of the capacity of the virus to trigger an
antitumor immune response we evaluated the therapeutic efﬁcacy
of Delta-24-RGD in immunocompetent models. First, animals
bearing NP53 subcutaneous tumors and treated with Delta-24-
RGD displayed a signiﬁcant lower tumor volume than those
treated with PBS (Two-tailed Student t test; P < 0.05; Fig. 5h).
Next, we evaluated the antitumor effect of Delta-24-RGD in
orthotopic immunocompetent mice bearing either NP53 or XFM
DIPG murine cell lines. The survival analyses showed that Delta-
24-RGD was able to signiﬁcantly increase the overall survival
of mice bearing NP53 or XFM (Log-rank Test; P= 0.01 and
P= 0.0002, respectively) (Fig. 5i and Supplementary Fig. 6f).
NP53-bearing mice treated with the virus showed a mean survival
of 26 days in comparison with 21 days in PBS-treated mice
and led to one (10%) long-term survivor mice (Fig. 5i). Most
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importantly, Delta-24-RGD treatment of XFM-bearing mice led
to 80% of long-term, compared with a median survival of 18 days
in PBS-treated XFM-bearing mice (Supplementary Fig. 6f). To
demonstrate the generation of an immune memory we performed
the reinjection of NP53 and XFM cell lines in the long-term
survivors of the previous experiments. Our data showed that
animals previously treated with Delta-24-RGD did not develop
tumors (Fig. 5j and Supplementary Fig. 6g). To demonstrate that
the antitumor response observed in the murine immunocompe-
tent models were owing to an immune response, we performed
similar experiments in athymic nude mice bearing either NP53
or XFM orthotopic tumors, as the replication of the virus is
highly attenuated in murine cell lines. As expected, treatment
with the virus did not present a survival beneﬁt in this model
(Log-rank test; P= 0.98 and P= 0.52, for NP53 and XFM,
respectively) (Fig. 5k and Supplementary Fig. 6h). These data
underscore the importance of the immune response in the
antitumor effect of the virus.
In summary, Delta-24-RGD infects, replicates, and kills DIPG
murine cells in vitro. Of importance, the in vivo administration
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are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10043-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2235 | https://doi.org/10.1038/s41467-019-10043-0 | www.nature.com/naturecommunications 7
triggers an immune response against DIPG tumors, leading to a
signiﬁcant increase in survival.
Discussion
The potential of oncolytic adenoviruses in the treatment of brain
tumors has been shown by various studies. In fact, several clinical
trials have evaluated the suitability of different oncolytic viruses
in adult patients with glioblastoma and showed promising
results14,20,21. The ability of oncolytic virotherapy to trigger an
immune response and the possibility of developing new armed
viruses with molecules that modulate the immune response have
opened new opportunities in cancer therapy
Regarding pediatric brain tumors, several preclinical studies
published during the prior 5 years have evaluated the efﬁcacy of
different oncolytic viruses22–24, and most of these works focused
on neuroblastoma25. For example, the intratumoral injection of
HSV1716, which is an oncolytic herpes virus, showed safety and
evidence of an immune response and viral replication in young
cancer patients26. In all of these studies, the oncolytic virus
administration displayed no toxicity at the speciﬁc doses admi-
nistered to the pediatric patients. Unfortunately, studies per-
formed in pHGG and DIPG are limited27, and the use of
oncolytic adenoviruses in high-grade pediatric brain tumors
continues to be vastly unexplored.
Delta-24-RGD has been widely studied in preclinical and,
recently, clinical trials (DNX-2401), demonstrating its safe proﬁle
and efﬁcacy against gliomas, but almost all studies were per-
formed in adult patients (NCT00805376, NCT01956734,
NCT02197169, NCT02798406). Recent studies have shown that
pHGG, including DIPG, differ from their counterparts in adults3.
Therefore, assessing Delta-24-RGD efﬁcacy in these tumors is
timely, as therapeutic options remain suboptimal. In this work,
we evaluate the suitability of Delta-24-RGD for the treatment of
pediatric gliomas, speciﬁcally pHGG and DIPG. Our data show
that all cell lines are susceptible to treatment with Delta-24-RGD.
We observed that the adenovirus had better antitumor effects in
pHGG and was correlated with a tendency to have a higher
replication in these cell lines. In Supplementary Fig. S2c there was
a statistically signiﬁcant difference in the replication between the
DIPG cell lines and the pHGG cells displayed. Delta-24-RGD
contains a 24 bp deletion in the E1A region; thus, viral replication
preferentially occurs in cells with a mutation in the RB pathway.
Genetic studies have shown that the RB1 mutation is more fre-
quent in hemispheric high-grade gliomas than brain stem tumors,
which might explain the higher susceptibility to Delta-24-RGD
replication and the higher cytotoxic effect observed in the pHGG
cells compared with those in the DIPG cells. In fact, Delta-24-
RGD has the strongest antitumor effect against PBT-24 cells,
which is a pediatric cell line derived from a child with hemi-
spheric high-grade glioma in which the RB protein was com-
pletely absent. Regarding DIPGs, in an elegant study performed
by Becher's group they showed that H3.3K27M repressed p16
tumor suppressor (CDKN2A), leading to an increase in pro-
liferation28. In addition, other study has shown that PDGF, highly
expressed in DIPGs, has the ability to stabilize E2F129. Therefore,
even though maybe the RB pathway is not always aberrant at the
genomic level (deletions of RB or p16/CDKN2A, ampliﬁcations
of cyclins or CDKs), there is always E2F1 free owing to uncon-
trolled replication of tumor cells. Therefore, this fact warrants
viral replication30.
Recent studies have shown the importance of the adenovirus
triggering of the immune response in the antitumor response
achieved in patients. The lack of relevant models of these types of
tumors until recently has also hindered the development of more-
tailored approaches. The development of immunocompetent
models that mimic the disease, at least partially31, have allowed us
to test our approach. Our study is important as we evaluate the
immune response triggered by an oncolytic adenovirus in two
different DIPG murine models. Our results show that Delta-24-
RGD administration in the pons of animals is safe and that
oncolytic adenovirus administration unleashes a potent immune
inﬁltration in the brain that is mainly circumscribed in the tumor
mass, most likely leading to tumor recognition by the immune
system. Our results are consistent with data obtained by Dr. Juan
Fueyo’s group14,32. The capacity of Delta-24-RGD to increase
lymphocyte inﬁltration in the brain opens the opportunity for
developing new combined strategies with immunotherapy.
Immunotherapy developed against DIPG has shown limited
results in patients owing to its incapability to cross the
blood–brain barrier and reach the tumor along with the strong
immunosuppressive microenvironment found in brain tumors33.
Among the immunotherapies that are currently being test in solid
pediatric cancer, are the immune checkpoint inhibitors and the
CAR T cells34. In addition to insufﬁcient therapeutic effects,
treatment using antibodies blocking CTLA-4 have induced the
same side effects in pediatric patients than in adults together
with insufﬁcient therapeutic effects35. In the case of treatment
utilizing CAR T cells, despite the encouraging responses observed
in liquid tumors, the therapeutic effect has been modest in solid
tumors and severe side effects have been reported including
(1) the cytokine release syndrome also found in therapeutic
monoclonal antibody36,37 (2) neurological toxicity, patients
receiving CD19-speciﬁc CAR T cells presented symptoms of
neurological damage38, and (3) on-target/off-tumor recognition,
when selected targets of CAR T cells are also expressed in normal
tissue; a fatal side-effect example was a patient treated with HER-
2/neu CAR T cell that developed a respiratory failure causing
patient death39. In contrast, administration of DNX-2401 in the
context of clinical trials did not show any severe adverse event in
either adults14 nor in DIPG patients40(and our unpublished
results). All together, the therapeutic effect of the Delta-24-RGD
is a combination of the virus replication capacity and the anti-
tumor effect triggered by it.
The encouraging results obtained in this work supported the
opening of a phase I/II clinical trial at our institution to evaluate
the safety and efﬁcacy of Delta-24-RGD administration followed
by RT in patients with newly diagnosed DIPG15. Importantly, as
a proof of principle, the administration of Delta-24-RGD
has proven to be safe in the ﬁrst cases40 (and our unpublished
results), with no further toxicity associated with either the biopsy
or injection of the virus, supporting the feasibility of this treat-
ment. The lack of severe side effects in this trial is in accordance
with the other Delta-24-RGD clinical trials where no adverse
effect grade IV has been recorded14,41.
In summary, here, we present evidence that Delta-24-RGD
could constitute a therapeutic option for the treatment of pHGG
and DIPG. The use of oncolytic viruses for the treatment of
pediatric brain tumors alone or in combination with other stra-
tegies could provide a breakthrough in the treatment of these
lethal diseases.
Methods
In silico analyses of pHGG and DMG/DIPG patient's samples. Gene expression
data from 220 pHGGs and diffuse midline H3-K27M gliomas were collected and
integrated as previously described1. In brief, gene expression data from an Affy-
metrix U133 plus 2 microarray, Agilent 44K transcriptome arrays and RNA
sequencing were annotated, normalized, and centered independently before being
combined, loss renormalized to remove platform bias and median centered. The
gene expression data were annotated by subgroup based on the integration of the
whole-genome and whole-exome sequencing and application of the Heidelberg
methylation classiﬁer for CNS tumors, resulting in six major subgroups
(H3.3G34R, H3.3K27_M, H3.1K27_M, IDH1, BRAF_PXA, and
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HGG_GBM_H3wt). To compare the absolute levels of expression in the Affymetrix
microarray data, rank measurements of the expression of cell surface markers were
compared with the present/absent thresholds of gene expression following RNA
and mass normalization in the affy package in R.
Cell lines and culture conditions. Pediatric glioma CHLA-03-AA cells were
obtained from the American Type Culture Collection (ATCC, Manassas, VA).
CHLA-200 and SJ-GBM2 were obtained from the Children’s Oncology Group
(COG Cell Line & Xenograft Repository). The PBT-24 pHGG cell line was
developed from a biopsy obtained at the University Clinic of Navarra from a 13-
year-old boy. The tumor samples were obtained with signed informed consent.
Ethical approval for the obtaining tumor samples was granted by the Ethical
Committee of the University of Navarra (CEI; Comité Etico de Investigación)
under the protocol numbers CEI-UN 2016-014. Tumors were cut into small pieces,
and the cells were enzymatically disaggregated. The cells obtained from the dis-
aggregation were cultured with Rosewell Park Memorial Institute medium sup-
plemented with 10% fetal bovine serum and 1% antibiotic. The cell lines obtained
from the ATCC or COG were cultured following the manufacturer’s speciﬁcations.
The SF188 cell line was kindly provided by Dr. Chris Jones (Cancer Research
Institute, Sutton, UK). The DIPG cell lines TP54, TP80, TP83, and TP84 were
kindly provided by Drs. Marie-Pierre Junier and Hervé Cheneiwess (INSERM
Institute, Paris, France); the SU-DIPG IV cell line was a kind gift from Dr. Michelle
Monje (Stanford, California); and JHH-DIPG1 and JHH-DIPG16A were gener-
ously provided by Dr. Eric Raabe (John Hopkins, Baltimore). All DIPG cell lines
were maintained as neurospheres cultured in a specialized serum-free basal med-
ium supplemented with a human neural stem cell proliferation supplement
(NeuroCultTM NS-A Proliferation Kit, #05751, STEMCELL Technologies), basic
ﬁbroblast growth factor and epidermal growth factor (20 ng/mL Sigma-Aldrich, St
Louis, MO). All cells were maintained in a humidiﬁed atmosphere containing 5%
CO2 at 37 °C. All cell lines were routinely tested for mycoplasma (Mycoalert
mycoplasma detection kit; Lonza) and authenticated at the CIMA Genomic Core
Facility (Pamplona, Spain) using DNA proﬁling. A description of the cell lines,
including the H3 mutational status, has been summarized in the Supplementary
Table 1.
The murine DIPG cell lines NP53 and XFM were provided by Dr. Becher
(Northwestern University, Illinois, USA)17,18. The cell lines were generated from
DIPG arising in genetically modiﬁed mice. The NP53 cell line was generated from a
tumor arising in a DIPG mouse model induced by PDGF-B signaling, TP53 loss,
and ectopic H3.3K27M17. The XFM cell line was generated from a tumor arising in
a mouse model driven by PDGF-B signaling and INK4A and ARF loss18.
Viral replication assays. The pHGG and DIPG cells were seeded at a density of
2 × 105 cells per well in six-well plates and infected with 10 MOIs of Delta-24-RGD.
After 3 days, the cells were collected, and the ﬁnal amount of virus was determined
by a method based on anti-hexon staining in HEK293 cells42.
Cell viability assay. The TP54, TP80, TP83, TP84, SU-DIPG IV, JHH-DIPG-1,
and JHH-DIPG-16A cells were seeded at a density of 1 × 104 cells/well, and PBT-
24, CHLA-03-AA, CHLA-200, and SJ-GBM2 were seeded at a density of 2 × 103
cells per well in 96-well plates. On the following day, the cells were infected with
Delta-24-RGD at different MOIs (5, 10, 25, 50, 100, and 300). The cell viability was
assessed after 5 days using an MTS assay (Promega) as previously described43. The
dose–response curves were analyzed using GradPath software. The IC50 value is the
median-effect dose (dose affecting 50% of the cells, i.e., 50% survival).
Immunoblotting. For the immunoblotting assays, the samples were subjected to
sodium dodecyl sulphate-Tris-glycine gel electrophoresis. The membranes were
incubated with the following antibodies: E1A, (1:1000; sc-430, Santa Cruz Bio-
technology, Santa Cruz, CA), ﬁber (1:1000; (4D2), NB600-541 Novus Biological,
Denver, CO), and GRB-2 (1:1000; 610111, BD biosciences). The membranes were
developed according to Amersham’s enhanced chemiluminescence protocol.
Animal studies. Ethical approval for the animal studies was granted by the Animal
Ethical Committee of the University of Navarra (CEEA; Comité Etico de Experi-
mentación Animal) under the protocol numbers CEEA/069-13 and 094-15. All
animal studies were performed at the veterinary facilities of the Center for Applied
Medical Research in accordance with institutional, regional, and national laws and
ethical guidelines for experimental animal care. For the orthotopic supratentorial
model, CHLA-03-AA and PBT-24 pHGG cells (5 × 105) were engrafted by injec-
tion into the caudate nucleus of athymic mice. The TP80 and TP54 cells (5 × 105)
developed DIPG tumors by injecting these cells into the pons of athymic mice, and
in both models, a guide-screw system was used44,45 (Taconic Farms, Inc). The
NP53 cells (104) were implanted in transgenic mice kindly provided by Dr. Oren
Becher, and the XFM cells (104) were implanted in BALB/c female mice. The cells
were administered in 3-4 μl of PBS. The animals were randomly assigned to the
following two groups: control mice injected with PBS and mice injected with Delta-
24-RGD. Delta-24-RGD (108 pfu per animal) was administered intracranially once
or three times (as indicated) in 3–4 μl 3 days after the cell implantation. In general,
we consider long-term survivors those animals that live at least two times longer
than the median survival of the control animals. In the case of murine models, in
which kinetics are very fast, we consider long-term survivors those animals that live
at least three times longer than the median survival of the control animals.
Immunohistochemical analysis. Parafﬁn-embedded sections of mice brains were
immunostained for antibodies speciﬁc to adenoviral mouse-hexon (1:1000;
AB1056, Millipore), adenovirus rabbit-E1A, (1:1000; Santa Cruz Bio-technology,
Santa Cruz, CA), CD3 (1:300; clon SP7, NeoMarkers, Fremont, CA), CD4 (1:1000;
EPR19514, ab183685 Abcam, Cambridge, MA) CD8a (1:1000, (D4W2Z) #98941
Cell Signaling, Danvers, MA) and FoxP3 (1:400; clon JFK-16s, ref. 14–5773
eBiosciences, Thermo Fisher, Waltham, MA) following conventional procedures.
For the immunohistochemical staining, Vectastain ABC kits (Vector Laboratories
Inc., Burlingame, CA) were used according to the manufacturer’s instructions.
Statistical analysis. For the in vitro experiments, the data are expressed as the
mean ± SD, and the comparisons were performed using two-tailed Student t tests.
The in vivo cytopathic effect of Delta-24-RGD on pHGG and DIPG xenografts was
assessed by plotting survival curves according to the Kaplan–Meier method. The
survival in different treatment groups was compared using a log-rank test. The
program GraphPad Prism 5 (Statistical Software for Sciences) was used for the
statistical analyses.
Data availability
The data that support the ﬁndings of this study are available within the paper or
Supplementary Information, or source data ﬁle or available from the corresponding
author upon request.
Received: 6 July 2018 Accepted: 16 April 2019
References
1. Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-
grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520–537 (2017).
2. Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and
pediatric non-brainstem high-grade glioma. Nat. Genet. 46, 444–450 (2014).
3. Jones, C. et al. Pediatric high-grade glioma: Biologically and clinically in need
of new thinking. Neuro. Oncol. 19, 153–161 (2017).
4. Louis, D. N. et al. The 2016 World Health Organization classiﬁcation of
tumors of the central nervous system: a summary. Acta Neuropathol. 131,
803–820 (2016).
5. Fangusaro, J. Pediatric high-grade gliomas and diffuse intrinsic pontine
gliomas. in. J. Child. Neurol. 24, 1409–1417 (2009).
6. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and other
central nervous system tumors diagnosed in the United States in 2009-2013.
Neuro. Oncol. 18, v1–v75 (2016).
7. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma in a
randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10, 459–466 (2009).
8. Warren, K. E. Diffuse intrinsic pontine glioma: poised for progress. Front.
Oncol. 2, 205 (2012).
9. Kline, C., Felton, E., Allen, I. E., Tahir, P. & Mueller, S. Survival outcomes in
pediatric recurrent high-grade glioma: results of a 20-year systematic review
and meta-analysis. J. Neurooncol. 137, 103–110 (2017).
10. Hassan, H., Pinches, A., Picton, S. V. & Phillips, R. S. Survival rates and
prognostic predictors of high grade brain stem gliomas in childhood: a
systematic review and meta-analysis. J. Neurooncol. 135, 13–20 (2017).
11. Grigg, C. et al. Talimogene laherparepvec (T-Vec) for the treatment of
melanoma and other cancers. Semin. Oncol. 43, 638–646 (2016).
12. Suzuki, K. et al. A conditionally replicative adenovirus with enhanced
infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120–126
(2001).
13. Fueyo, J. et al. Preclinical characterization of the antiglioma activity of a
tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
J. Natl. Cancer Inst. 95, 652–660 (2003).
14. Lang, F. F. et al. Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic
adenovirus: replication and immunotherapeutic effects in recurrent malignant
glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
15. Tejada, S. et al. Phase I Trial of DNX-2401 for diffuse intrinsic pontine
glioma newly diagnosed in pediatric patients. Neurosurgery 83, 1050–1056
(2017).
16. Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response
rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788
(2015).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10043-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2235 | https://doi.org/10.1038/s41467-019-10043-0 | www.nature.com/naturecommunications 9
17. Halvorson, K. G. et al. A high-throughput in vitro drug screen in a genetically
engineered mouse model of diffuse intrinsic pontine glioma identiﬁes BMS-
754807 as a promising therapeutic agent. PLoS ONE 10, e0118926 (2015).
18. Barton, K. L. et al. PD-0332991, a CDK4/6 Inhibitor, signiﬁcantly prolongs
survival in a genetically engineered mouse model of brainstem glioma.
PLoS ONE 8, e77639 (2013).
19. Blair, G. E., Dixon, S. C., Grifﬁths, S. A. & Zajdel, M. E. Restricted replication
of human adenovirus type 5 in mouse cell lines. Virus Res. 14, 339–346 (1989).
20. Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in
combination with radiation for recurrent GBM demonstrates safety and
radiographic responses. Mol. Ther. 22, 1048–1055 (2014).
21. Desjardins, A. et al. Recurrent glioblastoma treated with recombinant
poliovirus. N. Engl. J. Med. 379, 150–161 (2018).
22. Friedman, G. K. et al. Pediatric medulloblastoma xenografts including
molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing
by oncolytic herpes simplex viruses. Neuro. Oncol. 18, 227–235 (2016).
23. Studebaker, A. W. et al. Oncolytic herpes virus rRp450 shows efﬁcacy in
orthotopic xenograft group 3/4 medulloblastomas and atypical teratoid/
rhabdoid tumors. Mol. Ther. Oncolytics 6, 22–30 (2017).
24. Studebaker, A. W. et al. Oncolytic measles virus efﬁcacy in murine xenograft
models of atypical teratoid rhabdoid tumors. Neuro. Oncol. 17, 1568–1577 (2015).
25. Waters, A. M., Friedman, G. K., Ring, E. K. & Beierle, E. A. Oncolytic
virotherapy for pediatric malignancies: future prospects. Oncolytic Virother. 5,
73–80 (2016).
26. Streby, K. A. et al. Intratumoral injection of HSV1716, an oncolytic herpes
virus, is safe and shows evidence of immune response and viral replication
in young cancer patients. Clin. Cancer Res. 23, 3566–3574 (2017).
27. Cockle, J. V. et al. Oncolytic herpes simplex virus inhibits pediatric brain
tumor migration and invasion. Mol. Ther. Oncolytics 5, 75–86 (2017).
28. Cordero, F. J. et al. Histone H3.3K27M represses p16 to accelerate
gliomagenesis in a murine model of DIPG. Mol. Cancer Res. 15, 1243–1254
(2017).
29. Rahme, G. J. et al. PDGF engages an E2F-USP1 signaling pathway to support
ID2-mediated survival of proneural glioma cells. Cancer Res. 76, 2964–2976
(2016).
30. Gomez-Manzano, C., Yung, W. K. A., Alemany, R. & Fueyo, J. Genetically
modiﬁed adenoviruses against gliomas: from bench to bedside. Neurology 63,
418–426 (2004).
31. Misuraca, K. L., Cordero, F. J. & Becher, O. J. Pre-clinical models of diffuse
intrinsic pontine glioma. Front. Oncol. 5, 172 (2015).
32. Jiang, H. et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity
in an immunocompetent mouse model. PLoS ONE 9, e97407 (2014).
33. Miyauchi, J. T. & Tsirka, S. E. Advances in immunotherapeutic research for
glioma therapy. J. Neurol. 265, 741–756 (2018).
34. Majzner, R. G., Heitzeneder, S. & Mackall, C. L. Harnessing the
immunotherapy revolution for the treatment of childhood cancers. Cancer
Cell 31, 476–485 (2017).
35. Merchant, M. S. et al. Phase I clinical trial of ipilimumab in pediatric patients
with advanced solid tumors. Clin. Cancer Res. 22, 1364–1370 (2016).
36. Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and
management in CAR T-cell therapy. Mol. Ther. Oncolytics 3, 16011 (2016)
37. Wing, M. G. et al. Mechanism of ﬁrst-dose cytokine-release syndrome by
CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1)
on NK cells. J. Clin. Invest. 98, 2819–2826 (1996).
38. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute
lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial. Lancet 385, 517–528 (2015).
39. Morgan, R. A. et al. Case report of a serious adverse event following the
administration of t cells transduced with a chimeric antigen receptor
recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
40. Tejada, S. et al. DNX-2401, an oncolytic virus, for the treatment of newly
diagnosed diffuse intrinsic pontine gliomas: a case report. Front. Oncol. 8, 61
(2018).
41. Alonso M. M., et al. Oncolytic virus DNX-2401 with a short course of
temozolomide for glioblastoma at ﬁrst recurrence: clinical data and prognostic
biomarkers. in Proceedings of the American Association for Cancer Research
Annual Meeting 2017 . 77 (13 Suppl) (2017).
42. Cascallo, M. et al. Deletion of VAI and VAII RNA genes in the design of
oncolytic adenoviruses. Hum. Gene Ther. 17, 929–940 (2006).
43. Mosmann, T. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63 (1983).
44. Lal, S. et al. An implantable guide-screw system for brain tumor studies in
small animals. J. Neurosurg. 92, 326–333 (2000).
45. Marigil, M. et al. Development of a DIPG orthotopic model in mice using
an implantable guide-screw system. PLoS ONE 12, (2017).
Acknowledgements
We are very grateful to Dr. Laura Guembe and the imaging core for the help with all
the immunohistochemistry. This work was supported by the European Union (Marie
Curie IRG270459; to M.M. Alonso), the Instituto de Salud Carlos III y los Fondos Feder
Europeos (PI13/125; PI16/0066 to M.M. Alonso), the Spanish Ministry of Science
and Innovation (Ramón y Cajal contract RYC-2009–05571, IEDI-2015-00638, and
BIO2015-68990-REDT to M.M. Alonso), the Department of Health of the Government
of Navarra (to M.M. Alonso), the Basque Foundation for Health Research (BIOEF,
BIO13/CI/005), Foundation LA CAIXA/Caja Navarra (A-PG, MMA), Foundation “El
sueño de Vicky”, Asociation Pablo Ugarte-Fuerza Julen (A-PG,MMA), and DOD team
science award (MMA, JF, and CG-M). The Cancer Prevention and Research Institute of
Texas (RP170066; C-GM and JF, the Rory David Deutsch Foundation (OJB) and
Instituto de Salud Carlos III—CIBERONC (to JAM-C and MJG-B). This project has
received funding from the European Research Council (ERC) under the European
Union´s Horizon 2020 research and innovation programme (grant agreement No.
817884; ViroPedTher).
Author contributions
Conception and design: S.T.-S., R.D.-V., J.F., C.G.-M., A.P.-G. and M.M.A. Development
of methodology: N.M.-V., M.G.-M., M. Marigil, G.A., S.T.-S., R.D.-V. and M.M.A.
Acquisition of data (provided animals, acquired and managed patients, provided facil-
ities, etc.): All authors. Analysis and interpretation of the data (e.g., statistical analysis,
biostatistics, and computational analysis): N.M.-V., C.J., A.M. and M.M.A. Writing,
review, and/or revision of the manuscript: All authors. Administrative, technical, or
material support (i.e., reporting or organizing data and constructing databases): N.M.-V.,
M.G.-M., M.G.-H., M.P., J.G.P.-L., M.Z., L.M., M.V.-G., V.L., J.J.A., L.I.R., J.A.M.-C., M.J.
G.-B., G.A., H.J., M.P.J., H.C., E.A.E.-H., M.M.-D., O.J.B., E.R., A.P.-G. and M.M.A.
Study supervision: A.P.-G., C.G.-M., J.F. and M.M.A.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-10043-0.
Competing interests: H.J., C.G.-M. and J.F. report ownership interest (including patents)
in and are consultants for DNATrix. M.M.A., S.T.-S. and R.D.-V. report DNAtrix
sponsored research not related with this article. The remaining authors do not have
potential conﬂicts of interest to disclose.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Javad Nazarian and
the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10043-0
10 NATURE COMMUNICATIONS |         (2019) 10:2235 | https://doi.org/10.1038/s41467-019-10043-0 | www.nature.com/naturecommunications
